Immatics N.V. (IMTX)
NASDAQ: IMTX · Real-Time Price · USD
5.44
-0.15 (-2.68%)
At close: Jun 27, 2025, 4:00 PM
5.55
+0.11 (2.02%)
After-hours: Jun 27, 2025, 5:56 PM EDT
Immatics Employees
As of December 31, 2024, Immatics had 682 total employees, including 554 full-time and 128 part-time employees. The number of employees increased by 147 or 27.48% compared to the previous year.
Employees
682
Change (1Y)
147
Growth (1Y)
27.48%
Revenue / Employee
$228,449
Profits / Employee
-$35,495
Market Cap
661.23M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Abbott Laboratories | 114,000 |
AstraZeneca | 94,300 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
AbbVie | 55,000 |
IMTX News
- 4 weeks ago - Immatics IMA203 PRAME Cell Therapy Data Presented at 2025 ASCO Annual Meeting Continues to Show Strong Anti-tumor Activity and Durability in Patients with Metastatic Melanoma - GlobeNewsWire
- 6 weeks ago - Immatics Announces First Quarter 2025 Financial Results and Business Update - GlobeNewsWire
- 2 months ago - Immatics Announces Upcoming Oral and Poster Presentation on IMA203 TCR T-cell Therapy at 2025 ASCO Annual Meeting - GlobeNewsWire
- 3 months ago - Immatics N.V.: Trading Below Cash, But Not Without Reason - Seeking Alpha
- 3 months ago - Immatics Announces Full Year 2024 Financial Results and Business Update - GlobeNewsWire
- 7 months ago - Immatics Announces Third Quarter 2024 Financial Results, Business Update and First Clinical Data on TCER® IMA402 Targeting PRAME - GlobeNewsWire
- 8 months ago - Immatics Announces Multiple Presentations at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) on TCR-T Therapy Candidates Targeting PRAME - GlobeNewsWire
- 9 months ago - Immatics: A Promising TCR Pipeline - Seeking Alpha